Abstract Library

#1036 Abrogation of Autophagy by Chloroquine in Neuroendocrine Tumor Cells Treated with mTOR Inhibitors Induces Apoptosis, While Reduction of Cell Proliferation is Due to a Chloroquine, Autophagy Unrelated, Lysosomal Effect

Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Avniel- Polak S

Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Grozinsky-Glasberg S,

Keywords: NETs, autophagy, mTORi ,

#815 The Effect of Autophagy Inhibitors Alone or in Combination with mTOR Inhibitors in a Neuroendocrine Tumor Cell Model

Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Glasberg S

Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Glasberg S,

Keywords: NETs, autophagy, mTOR inhibitors,

#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience

Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Glaser B, Barak D, Fraenkel M, Gross D,

Keywords: MEN-1, hyperparathyroidism, pituitary tumors, gastroenteropancreatic tumors, menin,

#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience

Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Fraenkel M, Barak D, Mueller-Brand J, Krausz Y, Glaser B,

Keywords: PRRT, chronic complications, GEPNET,

#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry

Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Rodrigues M

Authors: Rodrigues M, Mirzaei S, Glaser K, Pokieser W,

Keywords: immunohistochemistry, Ki-67, CgA, synaptophysin, somatostatinreceptor scintigraphy, neuroendocrine tumours ,